HeartFlow announced today that John Farquhar has been appointed as the company’s president and CEO, effective today.
Farquhar, a former Medtronic executive, was appointed as COO of HeartFlow in August 2021 and has served as the company’s president and a member of the board since Jan. 1, 2022.
According to a news release, co-founder and CEO Dr. John H. Stevens will continue to serve on HeartFlow’s board of directors as vice chair after transitioning out of the CEO position.
“On behalf of the entire HeartFlow team, I want to thank John Stevens for his substantial contributions during his tenure as the company’s CEO,” HeartFlow Chairman William C. Weldon said in the release. “As a continuing board member, we will benefit from his drive towards maximizing value for all our stakeholders as we continue to transform the landscape of precision heart care.”
Before joining Mountain View, California-based HeartFlow, Farquhar was VP and GM of Medtronic’s aortic business, having also served in leadership roles for the company’s cardiovascular and diabetes groups.
“I am honored to have the opportunity to lead the company at this exciting time of growth,” Farquhar said. “HeartFlow’s AI-driven technology offers a compelling value proposition for both clinicians and patients and is enhancing the care paradigm for patients with coronary artery disease. I look forward to working with our talented and passionate team as we continue to evolve our business and technology.”
HeartFlow develops the non-invasive HeartFlow FFRCT analysis, which uses artificial intelligence to create a personalized three-dimensional heart model. The platform is commercially available in the United States, U.K., Canada, Europe and Japan.
The company is also developing the PreRead anatomic assessment and Plaque technology, it said, although they are currently under FDA review and not available for commercial use.
Last month, HeartFlow and special purpose acquisition company (SPAC) Longview Acquisition Corp. called off a previously announced $2.4 billion merger to take HeartFlow public in what was described as a mutual decision as a “result of current unfavorable market conditions.”
